xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06030206</url>
    </required_header>
    <id_info>
      <org_study_id>STUDY00016585</org_study_id>
      <secondary_id>1R01NR020470-01A1</secondary_id>
      <nct_id>NCT06030206</nct_id>
    </id_info>
    <brief_title>Lung Transplant READY CF 2: A Multi-site RCT</brief_title>
    <official_title>Preparation for Lung Transplant Discussions and Decisions Among People With Cystic Fibrosis</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of Washington</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>National Institute of Nursing Research (NINR)</agency>
        <agency_class>NIH</agency_class>
      </collaborator>
    </sponsors>
    <source>University of Washington</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In&#xD;
        the United States, more people with CF and low lung function die each year than undergo lung&#xD;
        transplant. More than half of people with CF who die without a lung transplant were never&#xD;
        referred for consideration. Patient preference not to undergo lung transplant may account for&#xD;
        25-40% of decisions to defer referral. Rates of death without transplant are higher for&#xD;
        people with CF who are members of marginalized communities, including those with Black race,&#xD;
        Hispanic ethnicity, or low socioeconomic status. Increasing awareness of lung transplant&#xD;
        among people with CF, and promoting understanding of the risks and benefits of transplant,&#xD;
        can potentially reduce the number of people with CF who die without a lung transplant.&#xD;
  &#xD;
        The CF Foundation (CFF) lung transplant referral guidelines were developed to optimize the&#xD;
        timing of referral for lung transplant. These guidelines recommend annual conversations with&#xD;
        people with CF once their forced expiratory volume in one second (FEV1) is &lt;50% predicted.&#xD;
        Considering lung transplant as a treatment option before it is medically needed will allow&#xD;
        more time to learn about lung transplant and address any barriers to lung transplant that may&#xD;
        exist.&#xD;
  &#xD;
        Investigators are interested in understanding how people with CF use lung transplant&#xD;
        educational resources and how one prepares for having discussions and/or making decisions&#xD;
        about lung transplant as a treatment option for advanced CF. The purpose of this study is to&#xD;
        test whether a research website improves patient preparedness for discussions about lung&#xD;
        transplant. Investigators also aim to understand whether there are unique factors that affect&#xD;
        people with CF from communities with decreased access to transplant (&quot;communities of&#xD;
        concern&quot;).&#xD;
  &#xD;
        Study involvement will span 6 months and study activities will involve the following:&#xD;
  &#xD;
          -  Four Zoom research sessions (15-30 minutes each)&#xD;
  &#xD;
          -  Survey assessments&#xD;
  &#xD;
          -  Access to a research website that contains educational resources about lung transplant&#xD;
  &#xD;
          -  Audio recording of a routine CF clinic visit to determine if and how lung transplant is&#xD;
             discussed between a participant and his/her/their CF doctor&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In&#xD;
        the United States, more people with CF with forced expiratory volume in 1 second (FEV1) less&#xD;
        than 30% of predicted die each year than undergo lung transplant. More than half of people&#xD;
        with CF who die without lung transplant were never referred for consideration, with patients&#xD;
        of lower socioeconomic status, Black race, or Hispanic ethnicity disproportionately impacted&#xD;
        by limited access to lung transplant. Patient preference not to undergo lung transplant may&#xD;
        account for 25-40% of decisions to defer referral. The CF Foundation established lung&#xD;
        transplant referral guidelines that recommend people with CF have annual conversations about&#xD;
        lung transplant with their CF doctor once their FEV1 is less than 50% of predicted.&#xD;
        Considering lung transplant as a treatment option before it is medically needed will allow&#xD;
        more time to learn about lung transplant and address any barriers to lung transplant that may&#xD;
        exist. By introducing an educational resource that can increase awareness of lung transplant&#xD;
        among patients, and promote understanding of the risks and benefits of lung transplant,&#xD;
        investigators aim to empower people with CF to take part in shared decision-making with their&#xD;
        CF providers, which could reduce the number of people with CF who die without lung&#xD;
        transplant.&#xD;
  &#xD;
        Based on prior research, investigators developed a novel lung transplant educational resource&#xD;
        that addresses patient-identified knowledge gaps and provides personalized educational&#xD;
        content to help people with CF prepare for lung transplant discussions and decisions. The&#xD;
        web-based educational resource couples real-life CF patient experiences of lung transplant in&#xD;
        the form of personal narratives with up-to-date, CF-specific, and guideline-based medical&#xD;
        information about lung transplant.&#xD;
  &#xD;
        The overall research objectives for this study are to test the efficacy of the&#xD;
        investigator-designed educational resource to improve patient preparedness for shared&#xD;
        decision making about lung transplant and knowledge about lung transplant, and to evaluate&#xD;
        the impact on mental health outcomes (depression and anxiety). The investigator-designed&#xD;
        website will be compared to an attention control website to better understand how people with&#xD;
        CF use and rank different educational resources' utility. The central hypothesis is that use&#xD;
        of the new investigator-designed website that incorporates disease severity data (FEV1 %&#xD;
        predicted, supplemental oxygen use, exacerbations) to identify relevant personal narratives&#xD;
        and guideline-based educational content will increase a patient's preparedness to engage in&#xD;
        discussions about lung transplant beyond the standard information presented on the attention&#xD;
        control website.&#xD;
  &#xD;
        The study will be a randomized controlled trial. Participants will be randomly assigned 1:1&#xD;
        to one of two educational resources, described above, stratified by FEV1 category (FEV1&#xD;
        30-50% or FEV1 &lt;30% of predicted), CF Center, and whether they are members of the&#xD;
        &quot;communities of concern&quot;). The communities of concern include people with Medicaid insurance,&#xD;
        high school education or less, Hispanic ethnicity, or Black/Asian/Other race (not White&#xD;
        race). Baseline surveys will evaluate knowledge about lung transplant, a Likert scale rating&#xD;
        of preparedness for lung transplant discussions, decisional conflict about lung transplant,&#xD;
        and mental health. For three months, participants will have access to one of two educational&#xD;
        resources via a login to a secure research website. At 2 weeks, there will be a study visit&#xD;
        that includes repeated surveys from baseline and the Preparedness for Shared Decision Making&#xD;
        (PrepDM) Scale. At 2 to 3 months after randomization, participants will have a routine CF&#xD;
        clinic visit, which may be audio-recorded for evaluation of lung transplant discussion. At 3&#xD;
        months after randomization, there will be a study visit that includes repeated surveys from&#xD;
        baseline and the PrepDM Scale. After the 3-month study visit, participants will have access&#xD;
        to both educational resources via individual login to the secure research website. At&#xD;
        6-months, there will be a study visit to repeat the surveys. Throughout the 6-months and for&#xD;
        a long-term follow up period of 4 years, web analytics will be captured at the individual&#xD;
        level to determine usage patterns for both educational resources.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">September 6, 2023</start_date>
    <completion_date type="Anticipated">July 31, 2027</completion_date>
    <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <primary_purpose>Other</primary_purpose>
      <masking>Double (Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Preparedness for Shared Decision Making (PrepDM) Scale</measure>
      <time_frame>Measured at the 3-month study visit</time_frame>
      <description>The primary endpoint is an intention-to-treat assessment of the difference in mean Preparedness for Shared Decision Making (PrepDM) Scale in the intervention versus attention-control arms of the study at the 3-month study visit using linear mixed models. Scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey)</measure>
      <time_frame>Measured at 3-month study visit</time_frame>
      <description>Difference in mean change in confidence-weighted true false (CTF) knowledge score will be measured in the intervention versus control arms of the study using linear mixed models. CTF scoring adds points for certainty in correct responses and deducts points for certainty in incorrect responses. Participants receive +2 points when &quot;sure&quot; about a correct response, +1 if unsure about a correct response, -1 if unsure about an incorrect response and -2 if sure about an incorrect response. For a 14-item knowledge test, the maximum score is +28 and the minimum score is -28, with higher scores indicating more knowledge about lung transplant.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Decisional Conflict Scale</measure>
      <time_frame>Baseline to 3-month study visit</time_frame>
      <description>Decisional Conflict Scale change will be measured from the baseline study visit to the 3-month study visit. The intention-to-treat analysis will compare mean change in the Decisional Conflict Scale between the intervention and control arms of the study. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Likert-scale rating of preparedness to discuss lung transplant (0-4)</measure>
      <time_frame>Measured at 3-month study visit</time_frame>
      <description>Likert rating of preparedness to discuss lung transplant will be measured at each study visit (0=Don't know, 1= Not at all prepared, 2 = A little prepared, 3 = Moderately prepared, 4 = Very prepared). The intention-to-treat analysis will compare mean change in Likert-scale rating between the intervention and attention-control arms of the study using linear mixed models.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Patient Health Questionnaire (PHQ-9)</measure>
      <time_frame>Measured at 3-month study visit</time_frame>
      <description>PHQ-9 is a scale that measures symptoms of depression in the prior 2 weeks on a 0-27 scale, with higher scores indicating worsening depression and a score of 10 or higher consistent with a diagnosis of depression. The intention-to-treat analysis will compare mean change in PHQ-9 between the intervention and attention-control arms of the study using linear mixed models. Investigators will also determine the proportion with new PHQ-9 score greater than or equal to 10 in each arm.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Generalized Anxiety Disorder 7-item (GAD-7) Scale</measure>
      <time_frame>Measured at 3-month study visit</time_frame>
      <description>GAD-7 is a scale that measures symptoms of anxiety in the prior 2 weeks on a 0-21 scale, with higher scores indicating worsening anxiety and a score of 10 or higher consistent with a diagnosis of generalized anxiety disorder. The intention-to-treat analysis will compare mean change in GAD-7 between the intervention and attention-control arms of the study using linear mixed models. Investigators will also determine the proportion with new GAD-7 score greater than or equal to 10 in each arm.</description>
    </secondary_outcome>
    <other_outcome>
      <measure>6-month assessment of Preparedness for Shared Decision Making (PrepDM) Scale</measure>
      <time_frame>Measured at 6-month study visit</time_frame>
      <description>The PrepDM Scale will be measured for all participants with respect to the investigator-designed educational resource (research intervention) and mean score will be compared for participants in the intervention (6 months of exposure) versus control arms (3 months of exposure) using linear mixed models. PrepDM scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.</description>
    </other_outcome>
    <other_outcome>
      <measure>6-month assessment for confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey)</measure>
      <time_frame>Measured at 6-month study visit</time_frame>
      <description>Change in confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) will be assessed from baseline to 6-months and from 3-month to 6-month study visits. Mean difference in the change in knowledge score will be compared between study arms for the two time periods (0 to 6 months and 3 to 6 months). Higher scores indicate more knowledge about lung transplant.</description>
    </other_outcome>
    <other_outcome>
      <measure>6-month assessment for Decisional Conflict Scale</measure>
      <time_frame>Measured at 6-months study visit</time_frame>
      <description>Change in Decisional Conflict Scale will be assessed from baseline to 6-months and from 3-month to 6-month study visits. Mean difference in the change in Decisional Conflict Scale will be compared between study arms for the two time periods (0 to 6 months and 3 to 6 months). Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].</description>
    </other_outcome>
    <other_outcome>
      <measure>6-month assessment for Likert-scale rating of preparedness to discuss lung transplant</measure>
      <time_frame>Measured at baseline, 3-month and 6-month study visits</time_frame>
      <description>Evaluate the proportion &quot;Very prepared&quot; at baseline, 3-months and 6-months in the intervention and control arms. Compare proportions across study arms at each time point.</description>
    </other_outcome>
    <other_outcome>
      <measure>Time spent using the research website</measure>
      <time_frame>Baseline to 3-month study visit</time_frame>
      <description>Average time spent using the research website from baseline to 3-months will be compared across study arms. Further, time spent using the investigator-designed website will be assessed as a predictor of: 1. change in confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) from baseline to 3-month study visit, 2. change in Likert preparedness from baseline to 3-month study visit, 3. change in Decisional Conflict Scale from baseline to 3-month study visit, and 4. mean PrepDM Scale at 3-months.</description>
    </other_outcome>
    <other_outcome>
      <measure>Between-arm comparisons of Shared Decision Making Questionnaire (SDM-Q-9)</measure>
      <time_frame>Routine CF Clinic visit during the trial</time_frame>
      <description>The analysis will be an intention-to-treat assessment of the difference in mean Shared Decision Making Questionnaire (SDM-Q-9) in the intervention versus attention-control arms of the study at the routine CF Clinic visit using linear mixed models. The SDM-Q-9 scale has a range of (0 to 45), with higher scores indicating higher quality of shared decision making from the patient's perspective. A change in SDM-Q-9 of 12 to 15 has been considered clinically meaningful.</description>
    </other_outcome>
    <other_outcome>
      <measure>Between-arm comparisons of Shared Decision Making Questionnaire for physicians (SDM-Q-doc)</measure>
      <time_frame>Routine CF Clinic visit during the trial</time_frame>
      <description>The analysis will be an intention-to-treat assessment of the difference in mean Shared Decision Making Questionnaire for physicians (SDM-Q-doc) in the intervention versus attention-control arms of the study at the routine CF Clinic visit using linear mixed models. The SDM-Q-doc scale has a range of (0 to 45), with higher scores indicating higher quality of shared decision making from the physician's perspective.</description>
    </other_outcome>
    <other_outcome>
      <measure>Preparedness for Shared Decision Making (PrepDM) Scale among members of communities of concern.</measure>
      <time_frame>Measured at 3-month study visit</time_frame>
      <description>In a prespecified subgroup analysis, investigators will assess the Preparedness for Shared Decision Making (PrepDM) Scale at 3 months within the cohort of participants who are members of communities of concern. This is an intention-to-treat assessment of the difference in mean Preparedness for Shared Decision Making (PrepDM) Scale in the intervention versus attention-control arms of the study at the 3-month study visit using linear mixed models in the subset of individuals who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). Scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.</description>
    </other_outcome>
    <other_outcome>
      <measure>Decisional Conflict Scale among members of communities of concern.</measure>
      <time_frame>Baseline to 3-month study visit</time_frame>
      <description>In a prespecified subgroup analysis, investigators will assess Decisional Conflict Scale change within the cohort of participants who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). Decisional Conflict Scale change will be measured from the baseline study visit to the 3-month study visit. The intention-to-treat analysis will compare mean change in the Decisional Conflict Scale between the intervention and control arms of the study in the subset of individuals who are members of communities of concern. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].</description>
    </other_outcome>
    <other_outcome>
      <measure>Confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) among members of communities of concern.</measure>
      <time_frame>Baseline to 3-month study visit</time_frame>
      <description>In a prespecified subgroup analysis, investigators will assess the difference in mean change from baseline to 3 months in Confidence-weighted true false (CTF) knowledge score will be measured in the intervention versus control arms of the study using linear mixed models within the cohort of participants who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). CTF scoring adds points for certainty in correct responses and deducts points for certainty in incorrect responses. Participants receive +2 points when &quot;sure&quot; about a correct response, +1 if unsure about a correct response, -1 if unsure about an incorrect response and -2 if sure about an incorrect response. For a 14-item knowledge test, the maximum score is +28 and the minimum score is -28, with higher scores indicating more knowledge about lung transplant.</description>
    </other_outcome>
    <other_outcome>
      <measure>Likert rating of preparedness to discuss lung transplant among members of communities of concern.</measure>
      <time_frame>Baseline to 3-month study visit</time_frame>
      <description>In a prespecified subgroup analysis, investigators will assess change from baseline to 3 months in Likert rating of preparedness to discuss lung transplant within the cohort of participants who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). The intention-to-treat analysis will compare mean change in the Likert rating of preparedness to discuss lung transplant between the intervention and control arms of the study in the subset of individuals who are members of communities of concern. Likert rating of preparedness to discuss lung transplant will be measured at each study visit (0=Don't know, 1= Not at all prepared, 2 = A little prepared, 3 = Moderately prepared, 4 = Very prepared).</description>
    </other_outcome>
    <other_outcome>
      <measure>Evaluation of CF Clinic audio-recordings and transcripts</measure>
      <time_frame>Routine CF Clinic visit (at least 6 weeks after randomization/until 3-Month Session) during the trial</time_frame>
      <description>Recordings will be listened to by at least two members of the study team for assessment or implicit bias (e.g. speech rate, verbal dominance) and whether the topic of LTx is raised with different frequency among participants from communities of concern.</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">132</enrollment>
    <condition>Cystic Fibrosis</condition>
    <arm_group>
      <arm_group_label>Intervention</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Access to an investigator-designed web-based educational resource with information about lung transplant for three months.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Attention-control</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Access to a publicly available web-based educational resource with information about transplant for three months.</description>
    </arm_group>
    <intervention>
      <intervention_type>Behavioral</intervention_type>
      <intervention_name>Investigator-designed lung transplant education resource (Research Intervention)</intervention_name>
      <description>Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.</description>
      <arm_group_label>Intervention</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Behavioral</intervention_type>
      <intervention_name>Publicly available transplant education resource (Attention-control)</intervention_name>
      <description>Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.</description>
      <arm_group_label>Attention-control</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Diagnosis of cystic fibrosis&#xD;
  &#xD;
            -  FEV1 less than 50% of predicted&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  People who are unable to provide informed consent&#xD;
  &#xD;
            -  People who are lung transplant recipients&#xD;
  &#xD;
            -  Unable to read or understand English or Spanish to complete surveys or access the&#xD;
               website (currently only available in English and Spanish)&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Kathleen Ramos, MD, MSc</last_name>
      <role>Principal Investigator</role>
      <affiliation>University of Washington</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Lauren Bartlett, BS, CCRC</last_name>
      <phone>503-583-2869</phone>
      <email>lrejman@uw.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>University of California at Los Angeles (UCLA)</name>
        <address>
          <city>Los Angeles</city>
          <state>California</state>
          <zip>980095</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>DeeAnna Serna</last_name>
        <phone>424-381-6507</phone>
        <email>DSerna@mednet.ucla.edu</email>
      </contact>
      <investigator>
        <last_name>Grant Turner, MD, MHA, FACP</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>National Jewish Health</name>
        <address>
          <city>Denver</city>
          <state>Colorado</state>
          <zip>80206</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Katie Poch, BS</last_name>
        <phone>303-398-1805</phone>
        <email>PochK@NJHealth.org</email>
      </contact>
      <investigator>
        <last_name>Milene Saavedra, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Yale University</name>
        <address>
          <city>New Haven</city>
          <state>Connecticut</state>
          <zip>06520</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Badrun Rahman</last_name>
        <phone>203-430-8391</phone>
        <email>badrun.rahman@yale.edu</email>
      </contact>
      <investigator>
        <last_name>Jonathan Koff, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Kansas</name>
        <address>
          <city>Kansas City</city>
          <state>Kansas</state>
          <zip>66160</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Mayank Kothari, MBBS, CCRC</last_name>
        <phone>913-588-2881</phone>
        <email>mkothari@kumc.edu</email>
      </contact>
      <investigator>
        <last_name>Charles Bengtson, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
      <investigator>
        <last_name>Joel Mermis, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Maine Health</name>
        <address>
          <city>Portland</city>
          <state>Maine</state>
          <zip>04102</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Emma Koukos</last_name>
        <phone>207-662-6550</phone>
        <email>Emma.Koukos@mainehealth.org</email>
      </contact>
      <investigator>
        <last_name>Edmund Sears, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Minnesota</name>
        <address>
          <city>Minneapolis</city>
          <state>Minnesota</state>
          <zip>55455</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Brooke Noren, RN, BSN, CCRC</last_name>
        <phone>612-625-7995</phone>
        <email>boer0039@umn.edu</email>
      </contact>
      <investigator>
        <last_name>Jordan Dunitz, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Cincinnati</name>
        <address>
          <city>Cincinnati</city>
          <state>Ohio</state>
          <zip>45267</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Nicole Hummel, LPN</last_name>
        <phone>513-558-7036</phone>
        <email>hummelne@ucmail.uc.edu</email>
      </contact>
      <investigator>
        <last_name>Veronica Indihar, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Pittsburgh</name>
        <address>
          <city>Pittsburgh</city>
          <state>Pennsylvania</state>
          <zip>15213</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Adrienne Dericco, BSN, RN, CCRC</last_name>
        <phone>412-692-8069</phone>
        <email>adrienne.dericco2@upmc.edu</email>
      </contact>
      <investigator>
        <last_name>Joseph Pilewski, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Washington Medical Center - Montlake</name>
        <address>
          <city>Seattle</city>
          <state>Washington</state>
          <zip>98195</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Lauren Bartlett, BS, CCRC</last_name>
        <phone>503-583-2869</phone>
        <email>lrejman@uw.edu</email>
      </contact>
      <investigator>
        <last_name>Kathleen Ramos, MD, MSc</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, Dunitz JM; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros. 2019 May;18(3):321-333. doi: 10.1016/j.jcf.2019.03.002. Epub 2019 Mar 27.</citation>
      <PMID>30926322</PMID>
    </reference>
    <reference>
      <citation>Hartzler AL, Bartlett LE, Hobler MR, Reid N, Pryor JB, Kapnadak SG, Berry DL, Lober WB, Goss CH, Ramos KJ; Take on Transplant Study Group. Take on transplant: human-centered design of a patient education tool to facilitate informed discussions about lung transplant among people with cystic fibrosis. J Am Med Inform Assoc. 2022 Dec 13;30(1):26-37. doi: 10.1093/jamia/ocac176.</citation>
      <PMID>36173364</PMID>
    </reference>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 25, 2023</study_first_submitted>
    <study_first_submitted_qc>September 6, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 8, 2023</study_first_posted>
    <last_update_submitted>September 8, 2023</last_update_submitted>
    <last_update_submitted_qc>September 8, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 11, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>University of Washington</investigator_affiliation>
      <investigator_full_name>Kathleen Ramos</investigator_full_name>
      <investigator_title>Associate Professor, School or Medicine</investigator_title>
    </responsible_party>
    <keyword>Cystic Fibrosis</keyword>
    <keyword>Lung Transplantation</keyword>
    <keyword>Advanced Lung Disease</keyword>
    <keyword>Decision Support Tool</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Cystic Fibrosis</mesh_term>
      <mesh_term>Fibrosis</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>De-identified individual participant data (IPD) may be shared with other researchers for secondary analyses with the approval of the appropriate Human Subjects Division(s) and the study's principal investigator (PI).</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
      <ipd_time_frame>Data will become available after publication of the results of the primary analyses of the study. The data will be available for up to 3 years after the end of the study.</ipd_time_frame>
      <ipd_access_criteria>Qualified researchers with appropriate clinical research training and/or mentorship will be allowed to have access to IPD after approval is obtained from Human Subjects Division(s) and the study PI.</ipd_access_criteria>
    </patient_data>
    <provided_document_section>
      <provided_document>
        <document_type>Study Protocol and Statistical Analysis Plan</document_type>
        <document_has_protocol>Yes</document_has_protocol>
        <document_has_icf>No</document_has_icf>
        <document_has_sap>Yes</document_has_sap>
        <document_date>June 9, 2023</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT06030206/Prot_SAP_000.pdf</document_url>
      </provided_document>
      <provided_document>
        <document_type>Informed Consent Form</document_type>
        <document_has_protocol>No</document_has_protocol>
        <document_has_icf>Yes</document_has_icf>
        <document_has_sap>No</document_has_sap>
        <document_date>August 29, 2023</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT06030206/ICF_001.pdf</document_url>
      </provided_document>
    </provided_document_section>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06030206
  org study id: STUDY00016585
  secondary id: 1R01NR020470-01A1
  nct id: NCT06030206
  lead sponsor: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In
        the United States, more people with CF and low lung function die each year than undergo lung
        transplant. More than half of people with CF who die without a lung transplant were never
        referred for consideration. Patient preference not to undergo lung transplant may account for
        25-40% of decisions to defer referral. Rates of death without transplant are higher for
        people with CF who are members of marginalized communities, including those with Black race,
        Hispanic ethnicity, or low socioeconomic status. Increasing awareness of lung transplant
        among people with CF, and promoting understanding of the risks and benefits of transplant,
        can potentially reduce the number of people with CF who die without a lung transplant.
  
        The CF Foundation (CFF) lung transplant referral guidelines were developed to optimize the
        timing of referral for lung transplant. These guidelines recommend annual conversations with
        people with CF once their forced expiratory volume in one second (FEV1) is <50% predicted.
        Considering lung transplant as a treatment option before it is medically needed will allow
        more time to learn about lung transplant and address any barriers to lung transplant that may
        exist.
  
        Investigators are interested in understanding how people with CF use lung transplant
        educational resources and how one prepares for having discussions and/or making decisions
        about lung transplant as a treatment option for advanced CF. The purpose of this study is to
        test whether a research website improves patient preparedness for discussions about lung
        transplant. Investigators also aim to understand whether there are unique factors that affect
        people with CF from communities with decreased access to transplant ("communities of
        concern").
  
        Study involvement will span 6 months and study activities will involve the following:
  
          -  Four Zoom research sessions (15-30 minutes each)
  
          -  Survey assessments
  
          -  Access to a research website that contains educational resources about lung transplant
  
          -  Audio recording of a routine CF clinic visit to determine if and how lung transplant is
             discussed between a participant and his/her/their CF doctor
  Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In
        the United States, more people with CF with forced expiratory volume in 1 second (FEV1) less
        than 30% of predicted die each year than undergo lung transplant. More than half of people
        with CF who die without lung transplant were never referred for consideration, with patients
        of lower socioeconomic status, Black race, or Hispanic ethnicity disproportionately impacted
        by limited access to lung transplant. Patient preference not to undergo lung transplant may
        account for 25-40% of decisions to defer referral. The CF Foundation established lung
        transplant referral guidelines that recommend people with CF have annual conversations about
        lung transplant with their CF doctor once their FEV1 is less than 50% of predicted.
        Considering lung transplant as a treatment option before it is medically needed will allow
        more time to learn about lung transplant and address any barriers to lung transplant that may
        exist. By introducing an educational resource that can increase awareness of lung transplant
        among patients, and promote understanding of the risks and benefits of lung transplant,
        investigators aim to empower people with CF to take part in shared decision-making with their
        CF providers, which could reduce the number of people with CF who die without lung
        transplant.
  
        Based on prior research, investigators developed a novel lung transplant educational resource
        that addresses patient-identified knowledge gaps and provides personalized educational
        content to help people with CF prepare for lung transplant discussions and decisions. The
        web-based educational resource couples real-life CF patient experiences of lung transplant in
        the form of personal narratives with up-to-date, CF-specific, and guideline-based medical
        information about lung transplant.
  
        The overall research objectives for this study are to test the efficacy of the
        investigator-designed educational resource to improve patient preparedness for shared
        decision making about lung transplant and knowledge about lung transplant, and to evaluate
        the impact on mental health outcomes (depression and anxiety). The investigator-designed
        website will be compared to an attention control website to better understand how people with
        CF use and rank different educational resources' utility. The central hypothesis is that use
        of the new investigator-designed website that incorporates disease severity data (FEV1 %
        predicted, supplemental oxygen use, exacerbations) to identify relevant personal narratives
        and guideline-based educational content will increase a patient's preparedness to engage in
        discussions about lung transplant beyond the standard information presented on the attention
        control website.
  
        The study will be a randomized controlled trial. Participants will be randomly assigned 1:1
        to one of two educational resources, described above, stratified by FEV1 category (FEV1
        30-50% or FEV1 <30% of predicted), CF Center, and whether they are members of the
        "communities of concern"). The communities of concern include people with Medicaid insurance,
        high school education or less, Hispanic ethnicity, or Black/Asian/Other race (not White
        race). Baseline surveys will evaluate knowledge about lung transplant, a Likert scale rating
        of preparedness for lung transplant discussions, decisional conflict about lung transplant,
        and mental health. For three months, participants will have access to one of two educational
        resources via a login to a secure research website. At 2 weeks, there will be a study visit
        that includes repeated surveys from baseline and the Preparedness for Shared Decision Making
        (PrepDM) Scale. At 2 to 3 months after randomization, participants will have a routine CF
        clinic visit, which may be audio-recorded for evaluation of lung transplant discussion. At 3
        months after randomization, there will be a study visit that includes repeated surveys from
        baseline and the PrepDM Scale. After the 3-month study visit, participants will have access
        to both educational resources via individual login to the secure research website. At
        6-months, there will be a study visit to repeat the surveys. Throughout the 6-months and for
        a long-term follow up period of 4 years, web analytics will be captured at the individual
        level to determine usage patterns for both educational resources.
  allocation: Randomized
  intervention model: Crossover Assignment
  primary purpose: Other
  masking: Double (Investigator, Outcomes Assessor)
  measure: Preparedness for Shared Decision Making (PrepDM) Scale
  time frame: Measured at the 3-month study visit
  description: The primary endpoint is an intention-to-treat assessment of the difference in mean Preparedness for Shared Decision Making (PrepDM) Scale in the intervention versus attention-control arms of the study at the 3-month study visit using linear mixed models. Scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.
  measure: Confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey)
  time frame: Measured at 3-month study visit
  description: Difference in mean change in confidence-weighted true false (CTF) knowledge score will be measured in the intervention versus control arms of the study using linear mixed models. CTF scoring adds points for certainty in correct responses and deducts points for certainty in incorrect responses. Participants receive +2 points when "sure" about a correct response, +1 if unsure about a correct response, -1 if unsure about an incorrect response and -2 if sure about an incorrect response. For a 14-item knowledge test, the maximum score is +28 and the minimum score is -28, with higher scores indicating more knowledge about lung transplant.
  measure: Decisional Conflict Scale
  time frame: Baseline to 3-month study visit
  description: Decisional Conflict Scale change will be measured from the baseline study visit to the 3-month study visit. The intention-to-treat analysis will compare mean change in the Decisional Conflict Scale between the intervention and control arms of the study. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].
  measure: Likert-scale rating of preparedness to discuss lung transplant (0-4)
  time frame: Measured at 3-month study visit
  description: Likert rating of preparedness to discuss lung transplant will be measured at each study visit (0=Don't know, 1= Not at all prepared, 2 = A little prepared, 3 = Moderately prepared, 4 = Very prepared). The intention-to-treat analysis will compare mean change in Likert-scale rating between the intervention and attention-control arms of the study using linear mixed models.
  measure: Patient Health Questionnaire (PHQ-9)
  time frame: Measured at 3-month study visit
  description: PHQ-9 is a scale that measures symptoms of depression in the prior 2 weeks on a 0-27 scale, with higher scores indicating worsening depression and a score of 10 or higher consistent with a diagnosis of depression. The intention-to-treat analysis will compare mean change in PHQ-9 between the intervention and attention-control arms of the study using linear mixed models. Investigators will also determine the proportion with new PHQ-9 score greater than or equal to 10 in each arm.
  measure: Generalized Anxiety Disorder 7-item (GAD-7) Scale
  time frame: Measured at 3-month study visit
  description: GAD-7 is a scale that measures symptoms of anxiety in the prior 2 weeks on a 0-21 scale, with higher scores indicating worsening anxiety and a score of 10 or higher consistent with a diagnosis of generalized anxiety disorder. The intention-to-treat analysis will compare mean change in GAD-7 between the intervention and attention-control arms of the study using linear mixed models. Investigators will also determine the proportion with new GAD-7 score greater than or equal to 10 in each arm.
  measure: 6-month assessment of Preparedness for Shared Decision Making (PrepDM) Scale
  time frame: Measured at 6-month study visit
  description: The PrepDM Scale will be measured for all participants with respect to the investigator-designed educational resource (research intervention) and mean score will be compared for participants in the intervention (6 months of exposure) versus control arms (3 months of exposure) using linear mixed models. PrepDM scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.
  measure: 6-month assessment for confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey)
  time frame: Measured at 6-month study visit
  description: Change in confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) will be assessed from baseline to 6-months and from 3-month to 6-month study visits. Mean difference in the change in knowledge score will be compared between study arms for the two time periods (0 to 6 months and 3 to 6 months). Higher scores indicate more knowledge about lung transplant.
  measure: 6-month assessment for Decisional Conflict Scale
  time frame: Measured at 6-months study visit
  description: Change in Decisional Conflict Scale will be assessed from baseline to 6-months and from 3-month to 6-month study visits. Mean difference in the change in Decisional Conflict Scale will be compared between study arms for the two time periods (0 to 6 months and 3 to 6 months). Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].
  measure: 6-month assessment for Likert-scale rating of preparedness to discuss lung transplant
  time frame: Measured at baseline, 3-month and 6-month study visits
  description: Evaluate the proportion "Very prepared" at baseline, 3-months and 6-months in the intervention and control arms. Compare proportions across study arms at each time point.
  measure: Time spent using the research website
  time frame: Baseline to 3-month study visit
  description: Average time spent using the research website from baseline to 3-months will be compared across study arms. Further, time spent using the investigator-designed website will be assessed as a predictor of: 1. change in confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) from baseline to 3-month study visit, 2. change in Likert preparedness from baseline to 3-month study visit, 3. change in Decisional Conflict Scale from baseline to 3-month study visit, and 4. mean PrepDM Scale at 3-months.
  measure: Between-arm comparisons of Shared Decision Making Questionnaire (SDM-Q-9)
  time frame: Routine CF Clinic visit during the trial
  description: The analysis will be an intention-to-treat assessment of the difference in mean Shared Decision Making Questionnaire (SDM-Q-9) in the intervention versus attention-control arms of the study at the routine CF Clinic visit using linear mixed models. The SDM-Q-9 scale has a range of (0 to 45), with higher scores indicating higher quality of shared decision making from the patient's perspective. A change in SDM-Q-9 of 12 to 15 has been considered clinically meaningful.
  measure: Between-arm comparisons of Shared Decision Making Questionnaire for physicians (SDM-Q-doc)
  time frame: Routine CF Clinic visit during the trial
  description: The analysis will be an intention-to-treat assessment of the difference in mean Shared Decision Making Questionnaire for physicians (SDM-Q-doc) in the intervention versus attention-control arms of the study at the routine CF Clinic visit using linear mixed models. The SDM-Q-doc scale has a range of (0 to 45), with higher scores indicating higher quality of shared decision making from the physician's perspective.
  measure: Preparedness for Shared Decision Making (PrepDM) Scale among members of communities of concern.
  time frame: Measured at 3-month study visit
  description: In a prespecified subgroup analysis, investigators will assess the Preparedness for Shared Decision Making (PrepDM) Scale at 3 months within the cohort of participants who are members of communities of concern. This is an intention-to-treat assessment of the difference in mean Preparedness for Shared Decision Making (PrepDM) Scale in the intervention versus attention-control arms of the study at the 3-month study visit using linear mixed models in the subset of individuals who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). Scores range on a scale from 0 to 100 with higher scores indicating a higher perceived level of preparation for decision making.
  measure: Decisional Conflict Scale among members of communities of concern.
  time frame: Baseline to 3-month study visit
  description: In a prespecified subgroup analysis, investigators will assess Decisional Conflict Scale change within the cohort of participants who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). Decisional Conflict Scale change will be measured from the baseline study visit to the 3-month study visit. The intention-to-treat analysis will compare mean change in the Decisional Conflict Scale between the intervention and control arms of the study in the subset of individuals who are members of communities of concern. Scores range from 0 [no decisional conflict] to 100 [extremely high decisional conflict].
  measure: Confidence-weighted true false knowledge about lung transplant (14-question investigator-designed survey) among members of communities of concern.
  time frame: Baseline to 3-month study visit
  description: In a prespecified subgroup analysis, investigators will assess the difference in mean change from baseline to 3 months in Confidence-weighted true false (CTF) knowledge score will be measured in the intervention versus control arms of the study using linear mixed models within the cohort of participants who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). CTF scoring adds points for certainty in correct responses and deducts points for certainty in incorrect responses. Participants receive +2 points when "sure" about a correct response, +1 if unsure about a correct response, -1 if unsure about an incorrect response and -2 if sure about an incorrect response. For a 14-item knowledge test, the maximum score is +28 and the minimum score is -28, with higher scores indicating more knowledge about lung transplant.
  measure: Likert rating of preparedness to discuss lung transplant among members of communities of concern.
  time frame: Baseline to 3-month study visit
  description: In a prespecified subgroup analysis, investigators will assess change from baseline to 3 months in Likert rating of preparedness to discuss lung transplant within the cohort of participants who are members of communities of concern (Medicaid insurance, high-school education or less, Hispanic ethnicity, Black/Asian/Other race). The intention-to-treat analysis will compare mean change in the Likert rating of preparedness to discuss lung transplant between the intervention and control arms of the study in the subset of individuals who are members of communities of concern. Likert rating of preparedness to discuss lung transplant will be measured at each study visit (0=Don't know, 1= Not at all prepared, 2 = A little prepared, 3 = Moderately prepared, 4 = Very prepared).
  measure: Evaluation of CF Clinic audio-recordings and transcripts
  time frame: Routine CF Clinic visit (at least 6 weeks after randomization/until 3-Month Session) during the trial
  description: Recordings will be listened to by at least two members of the study team for assessment or implicit bias (e.g. speech rate, verbal dominance) and whether the topic of LTx is raised with different frequency among participants from communities of concern.
  arm group label: Intervention
  arm group type: Experimental
  description: Access to an investigator-designed web-based educational resource with information about lung transplant for three months.
  arm group label: Attention-control
  arm group type: Active Comparator
  description: Access to a publicly available web-based educational resource with information about transplant for three months.
  intervention type: Behavioral
  intervention name: Investigator-designed lung transplant education resource (Research Intervention)
  description: Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.
  arm group label: Intervention
  intervention type: Behavioral
  intervention name: Publicly available transplant education resource (Attention-control)
  description: Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
  arm group label: Attention-control
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Kathleen Ramos, MD, MSc
  role: Principal Investigator
  affiliation: University of Washington
  last name: Lauren Bartlett, BS, CCRC
  phone: 503-583-2869
  email: lrejman@uw.edu
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  country: United States
  citation: Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, Dunitz JM; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros. 2019 May;18(3):321-333. doi: 10.1016/j.jcf.2019.03.002. Epub 2019 Mar 27.
  PMID: 30926322
  citation: Hartzler AL, Bartlett LE, Hobler MR, Reid N, Pryor JB, Kapnadak SG, Berry DL, Lober WB, Goss CH, Ramos KJ; Take on Transplant Study Group. Take on transplant: human-centered design of a patient education tool to facilitate informed discussions about lung transplant among people with cystic fibrosis. J Am Med Inform Assoc. 2022 Dec 13;30(1):26-37. doi: 10.1093/jamia/ocac176.
  PMID: 36173364
  responsible party type: Principal Investigator
  investigator affiliation: University of Washington
  investigator full name: Kathleen Ramos
  investigator title: Associate Professor, School or Medicine
  mesh term: Cystic Fibrosis
  mesh term: Fibrosis
  sharing ipd: Yes
  ipd description: De-identified individual participant data (IPD) may be shared with other researchers for secondary analyses with the approval of the appropriate Human Subjects Division(s) and the study's principal investigator (PI).
  ipd info type: Study Protocol
  ipd info type: Informed Consent Form (ICF)
  ipd time frame: Data will become available after publication of the results of the primary analyses of the study. The data will be available for up to 3 years after the end of the study.
  ipd access criteria: Qualified researchers with appropriate clinical research training and/or mentorship will be allowed to have access to IPD after approval is obtained from Human Subjects Division(s) and the study PI.
  provided document: 
  provided document: 